Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.
3.

Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.

Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y.

Med Pediatr Oncol. 2001 Jan;36(1):203-4.

PMID:
11464885
5.

Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.

Kuroda T, Saeki M, Nakano M, Mizutani S.

J Pediatr Surg. 1997 Jan;32(1):69-72.

PMID:
9021573
7.

MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.

Grau E, Oltra S, Martínez F, Orellana C, Cañete A, Fernández JM, Hernández-Martí M, Castel V.

J Cancer Res Clin Oncol. 2009 Apr;135(4):523-31. doi: 10.1007/s00432-008-0484-1. Epub 2008 Sep 27.

PMID:
18820946
8.

Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.

Zhang S, Zhou X, Yu H, Yu Y.

BMC Cancer. 2010 Apr 27;10:163. doi: 10.1186/1471-2407-10-163.

9.

Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.

Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P, Lewis IJ.

Med Pediatr Oncol. 2001 Jan;36(1):213-9.

PMID:
11464888
11.

Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.

Ito R, Asami S, Kagawa S, Motohashi S, Shichino H, Chin M, Yoshida Y, Nemoto N, Mugishima H, Suzuki T.

Biol Pharm Bull. 2004 Mar;27(3):315-8.

12.

Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.

Lambooy LH, Gidding CE, van den Heuvel LP, Hulsbergen-van de Kaa CA, Ligtenberg M, Bökkerink JP, De Abreu RA.

Clin Cancer Res. 2003 Feb;9(2):812-9.

13.

Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium -111-pentetreotide.

Orlando C, Raggi CC, Bagnoni L, Sestini R, Briganti V, La Cava G, Bernini G, Tonini GP, Pazzagli M, Serio M, Maggi M.

Med Pediatr Oncol. 2001 Jan;36(1):224-6.

PMID:
11464890
14.

GD2 synthase: a new molecular marker for detecting neuroblastoma.

Lo Piccolo MS, Cheung NK, Cheung IY.

Cancer. 2001 Aug 15;92(4):924-31.

PMID:
11550167
15.

Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.

Pession A, Libri V, Sartini R, Conforti R, Magrini E, Bernardi L, Fronza R, Olivotto E, Prete A, Tonelli R, Paolucci G.

Oncol Rep. 2003 Mar-Apr;10(2):357-62.

PMID:
12579272
16.
17.

Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.

Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, Pantel K, Riethmüller G.

Cancer Res. 2002 Jan 1;62(1):251-61.

18.

A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer.

Mecklenburg I, Weckermann D, Zippelius A, Schoberth A, Petersen S, Prang N, Riethmüller G, Kufer P.

J Immunol Methods. 2007 Jun 30;323(2):180-93. Epub 2007 May 15.

PMID:
17540401
19.

Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.

Swerts K, De Moerloose B, Dhooge C, Vandesompele J, Hoyoux C, Beiske K, Benoit Y, Laureys G, Philippé J.

Clin Chem. 2006 Mar;52(3):438-45. Epub 2005 Dec 29.

20.

Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.

Bozzi F, Luksch R, Collini P, Gambirasio F, Barzanò E, Polastri D, Podda M, Brando B, Fossati-Bellani F.

Diagn Mol Pathol. 2004 Sep;13(3):135-43.

PMID:
15322424
Items per page

Supplemental Content

Write to the Help Desk